Please login to the form below

Not currently logged in
Email:
Password:

Boehringer - Lilly file empagliflozin for European approval

EMA begins review of the companies' new type 2 diabetes drug

Empaglifozin moleculeThe European Medicines Agency (EMA) has begun its review of Boehringer Ingelheim and Lilly's new oral type 2 diabetes drug empagliflozin.

The treatment is a sodium glucose co-transporter-2 (SGLT-2) inhibitor, the same new class of type 2 diabetes treatment as Bristol-Myers Squibb and AstraZeneca's Foxiga and Johnson & Johnson's canaglifozin.

SGLT-2 inhibitors work independently of insulin and appear to provide sustained improvements in blood glucose, whilst also alleviating the weight gain seen with other oral anti-diabetic agents (OADs).

“We are pleased the EMA has accepted our marketing authorisation application for a potential new treatment option to help patients better manage their type 2 diabetes mellitus,” said Prof Klaus Dugi, corporate senior vice president medicine, Boehringer Ingelheim.

The European filing follows empagliflozin's recent submission to US regulators for approval, giving it a chance to catch up with its rival SGLT-2 inhibitors.

Bristol-Myers Squibb and AstraZeneca's Forxiga (dapagliflozin) has already been approved in the EU, but delayed in the US, while Johnson & Johnson's canagliflozin has been filed for approval in the US and Europe.

Empagliflozin is one of the four compounds covered by Boehringer and Lilly's 2011 co-development agreement.

Early this year Lilly took back sole development and marketing rights to LY2605541 - a basal insulin product, but the partners are still working together on Tadjenta (linagliptin) and LY2963016, a second basal insulin analogue.

28th March 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Liberation Unlimited

'Progressive', 'cutting edge' – words used to describe Liberation Unlimited. We believe looking forward is essential to delivering successful and...

Latest intelligence

UK life sciences minister George Freeman
Creating a 21st century life sciences ecosystem
The UK’s life sciences minister on how government and pharma can encourage NHS uptake and innovation...
Improving Corporate Memory as a Patient Safety Strategy
An article by Lorri Zipperer...
Online Physician Communities
How can pharma innovate in child and TYA cancer?
by Dr Tim Ringrose, M3 (EU)...